Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

23 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

olodaterol Articles

FDA advisory panel backs Boehringer's COPD drug olodaterol

30 January 2013

Forest launches COPD product Tudorza in USA

12 December 2012

Boehringer Ingelheim highlights robust respiratory R&D pipeline; announces investment

1 November 2012

Boehringer reveals new data on olodaterol and tiotropium combo at ERS

4 September 2012

COPD market to grow to more than $13.4 billion in 2020

19 December 2011

Showing 1-5 of 5 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS